Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Cali Pharmaceuticals General Information
Cali Pharmaceuticals is advancing CPL‑01, an extended-release formulation of ropivacaine for perioperative pain. The company has completed a Phase 2b trial showing promising efficacy and safety results in postoperative pain after bunionectomy. Two pivotal Phase 3 studies are ongoing to further evaluate efficacy and opioid-sparing effects in surgical patients.[3][5]
Contact Information
Website
Primary Industry
Biotech
Corporate Office
San Diego, California
USA
USA
Drug Pipeline
ropivacaine
Phase 2Key Partnerships
Grand Life Sciences announced strategic collaboration with parent company for commercialization of CPL‑01.[1]
Cali Pharmaceuticals Funding
No funding data available
To view Cali Pharmaceuticals's complete valuation and funding history, request access »